Background
==========

Breast cancer is the most common female cancer in Western countries \[[@b1-medscimonit-20-1155]\]. In Taiwan, breast cancer is the leading cause of cancer and is the fourth-ranked cause of cancer death. In Taiwan in 2010, more than 7500 breast cancers were diagnosed, causing 1600 deaths. The Health Promotion Administration, Ministry of Health and Welfare (Taiwan), provides biennial breast cancer mammogram screening for women aged 45--69 years and to women older than 40 with high risk.

Axillary lymph node metastasis (ALNM) is the most important prognostic factor in patients with invasive breast cancer \[[@b2-medscimonit-20-1155]--[@b6-medscimonit-20-1155]\]. Patients without axillary nodal involvement have a more favorable prognosis. Metastases to more than 6 nodes demonstrated the risk of distant metastasis. In recent years, the concept of sentinel lymph node sampling has greatly change surgical procedure in breast cancer. With the advance of sentinel lymph node sampling, it has rapidly replaced standard axillary lymph node dissection in patients who are clinically axillary node metastasis negative. Pre-operative assessment of axillary condition has become an essential issue in surgical planning. Researchers began to search for tumor characteristics related to axillary nodal metastasis. The aim of this study was to identify tumor characteristics associated with axillary lymph node metastasis. We studied consecutive patients with invasive breast cancer who underwent surgical breast and axillary procedures in our hospital and determined the predictive factor of axillary nodal disease by structure equation model (SEM). We hope to improve cancer counseling and provide optimal surgical planning in high-risk patients pre-operatively.

Material and Methods
====================

Patient population
------------------

We conducted a review analysis of retrospective databases of patients diagnosed with invasive breast cancer at Changhua Christian Hospital between January 2004 and January 2010. This study was approved by the institutional review board and the ethics committee of the Changhua Christian Hospital. A population of 1325 patients was identified. Their medical charts and treatments were retrospectively reviewed for information on tumor characteristics. The inclusion criteria were: (1) female breast cancers diagnosed and treated at our hospital, and (2) patients with complete medical information. Patients were excluded from this study if they had ductal carcinoma *in situ* or if they were treated with neoadjuvant therapy, had bilateral breast cancers, or if clinical data were not complete. All patients underwent breast-conserving surgery with axillary lymph node dissection, sentinel lymph node sampling, or modified radical mastectomy.

Data collection
---------------

The clinical characteristics included age at diagnosis, tumor size, lymph node metastasis, histology grade, hormonal receptor (estrogen receptor and progesterone receptor) status, human epidermal growth factor receptor 2 (HER2) status, and the presence of lymphovascular invasion (LVI). The quality of the cancer registry database was reviewed and approved by a committee of radiologists, oncologists, pathologists, and surgeons, as well as an epidemiologist with special expertise in breast cancer. The hormonal receptor status was tested based on standard immunostaining. For determination of HER2 expression, immunohistochemical staining assay and semiquantitative scoring were used. No or weak incomplete membrane staining (0 to 1+) was considered to be a negative result; 2+ staining with complete membrane was considered as equivocal over-expression; and 3+ staining was considered over-expression. Patients with equivocal HER2 over-expression were further assessed by fluorescence *in situ* hybridization method.

Statistics analysis
-------------------

Data analysis was conducted with SPSS (Statistical Package for Social Science) 16.0 version. SEM was used to examine the proposed model. Continuous variables were expressed as the mean ± standard deviation (SD). Categorical data were tested by the chi-square test. All *p* values were two-tailed. A *p* value less than 0.05 was considered as statistically significant. AMOS (Analysis of Moment Structure) 16.0 version was applied to perform SEM. Model fitting: chi-squared values were significant (*p*\<0.05) and the fit indices had value more than 0.9, which indicated good model fit.

Results
=======

There were 1325 female patients include in this analysis, with an average age of 51.3 years old (SD=11.2). Mean tumor size was 2.4 cm (SD=1.5). Patients were divided into 2 groups: ALNM-positive and ALNM-negative. A total of 583 axillary lymph node involvements were ascertained. [Table 1](#t1-medscimonit-20-1155){ref-type="table"} showed patient clinical features and tumor characteristics of 1325 cases. Clinical features and tumor characteristics among women with breast cancer were analyzed according to the axillary lymph node status. There was no significant difference between 2 groups with regard to age or estrogen receptor. The distributions of tumor size, histology grade, progesterone receptor, and HER2 within the 2 groups were significantly different.

Univariate Cox regression analysis of factors associated with axillary lymph node metastases was performed ([Table 2](#t2-medscimonit-20-1155){ref-type="table"}). Five variables were found to be significant in the univariate analysis. They included tumor size, progesterone receptor, HER2 status, LVI, and histology grade. Tumor size was highly associated with axillary nodal involvement and increasing size with an increasing risk of ALNM (odds ratio =1.56, 95% confidence interval: 1.423 to 1.708, *p*\<0.0001). A poor histology grade (odds ratio =1.69, *p*=0.0008) and presence of LVI (odds ratio =9.282, *p*\<0.0001) were also a significant factor for axillary nodal disease. Progesterone receptor positivity (*p*=0.0032) and HER2 over-expression (*p*=0.002) were significantly associated with positive axillary status. A multivariate logistic regression model was applied and results are presented in [Table 2](#t2-medscimonit-20-1155){ref-type="table"}. In this model, the data showed that tumor size, LVI, and histology grade were associated with statistically significant differences in axillary nodal metastases (*p*\<0.05). The relation between clinical and pathologic factors with ALNM is shown in [Table 3](#t3-medscimonit-20-1155){ref-type="table"}. The clinical and pathology factors, as well as tumor size, progesterone receptor, HER2, LVI, and histology grade, were highly correlated with ALNM. To determine the causal relationship among those factors, we conducted a structured equation model to build a pathway analyses. We used SEM to test the proposed model because it showed the correlation among all the variables, as well as showing the direction of the path among all the variables. Within the model, the clinical and pathology factors were defined as those variables highly associated with ALNM. [Figure 1A](#f1-medscimonit-20-1155){ref-type="fig"} presents the proposed model of this study. This model was used to test the hypothesis. All variables, including clinical factors and pathological factors, were calculated in the model, including HER2, progesterone receptor, histology grade, tumor size, and LVI. The model was further modified to improve the fit. [Figure 1B](#f1-medscimonit-20-1155){ref-type="fig"} was the final model of this study. In this model, 4 independent predictors of ALNM were identified. The optimal pathway among the 4 factors in the final model was that HER2 status might have influenced ALNM through histology grade (β=0.18), and then tumor size (β=0.16). Tumor size was highly relevant to LVI and influenced ALNM through LVI (β=0.26). The strongest predictor of ALNM in the final model was LVI (β=0.46), followed by histology grade, tumor size, and HER2 status. LVI was the highest risk factor for ALNM (odds ratio =9.282; 95% confidence interval: 7.218--11.936).

Discussion
==========

Axillary nodal status is the crucial factor in cancer staging of female breast cancer. It is also an important prognostic factor for cancer survival \[[@b7-medscimonit-20-1155]--[@b9-medscimonit-20-1155]\]. Complete axillary lymph node dissection is the criterion standard for assessment of metastases. With advancements in surgical technique, sentinel lymph node (SLN) biopsy has become popular in clinical axillary node negative patients \[[@b10-medscimonit-20-1155]\]. SLN biopsy reduces the morbidity and complications of axillary lymphatic drainage and major vessel and nerve injury \[[@b11-medscimonit-20-1155]\]. Breast cancer screening program in Taiwan have evolved since 1995 \[[@b12-medscimonit-20-1155]\]. An increase in breast cancer incidence was noted in Taiwan; fortunately, these tumors were being found at a smaller size than before and usually with less invasive axillary involvement; therefore, patients with small tumors might be benefit from SLN biopsy. Assessment of axillary status has become a key step in cancer counseling and pre-operative planning.

Clinical features and pathologic characteristics are important information in the pre-operative treatment of breast cancer. Physicians have been searching for favorable categories in axillary node evaluation \[[@b4-medscimonit-20-1155],[@b13-medscimonit-20-1155]--[@b15-medscimonit-20-1155]\]. There remains much debate about the correct clinical pathway of ALNM. In 1997 Barth et al. found LVI, tumor size, and histology grade can be used to estimate the risk of ALNM \[[@b15-medscimonit-20-1155]\]. Among these characteristics, LVI is the strongest predictor of ALNM \[[@b15-medscimonit-20-1155]--[@b23-medscimonit-20-1155]\]. The presence of LVI is highly associated with ALNM. The odds ratio (LVI presence *vs.* negative) is high in extensive axillary nodal involvement. A low percentage of ALNM is found in small tumors with negative LVI \[[@b16-medscimonit-20-1155]\]. Previous research showed that the predictive power was strong in non-SLN metastases \[[@b23-medscimonit-20-1155]\]. LVI also increases the incidence of isolated tumor cells in SLN \[[@b24-medscimonit-20-1155]\]. In our study, LVI was the strongest predictor of ALNM (odds ratio =8.2), which is concordant with the other published series referenced above. Patients with LVI are not good candidates for SLN biopsy and should be treated more aggressively.

Tumor size is a traditional predictor in axillary lymph node status. Our study demonstrates tumor size is the significant independent predictive factor in univariant and multivariant analysis. Patients with tumor size more than 40 mm are 3 times more likely to have axillary nodal involvement ([Table 1](#t1-medscimonit-20-1155){ref-type="table"}). In agreement with previous publications, patients with larger tumor size have increased risk of ALNM \[[@b14-medscimonit-20-1155],[@b15-medscimonit-20-1155],[@b25-medscimonit-20-1155]--[@b27-medscimonit-20-1155]\]. Breast cancer with smaller tumors (\<20 mm in our study) might benefit from sentinel lymph node biopsy \[[@b28-medscimonit-20-1155]\]. In patients with moderate-sized tumors (20--40 mm), the risk of ALNM is relatively high and should be evaluated based on tumor characteristics and other examination tools because of the probability of need for a secondary axillary operation. In patients with large tumor size (\>40 mm), complete axillary lymph node dissection is a preferred surgical procedure, based on the high probability of ALNM.

HER2 is associated with higher aggressiveness in invasive breast cancer, and is accepted as an important prognostic factor in breast cancer patients \[[@b29-medscimonit-20-1155]\]. However, the association between HER2 and ALNM is not clearly identified. In our research, HER2 is a significant predictor in univariant analysis (odds ratio =1.53). We constructed an optimal predictive model to differentiate the clinical pathway of ALNM and tumor characteristics.

In the structure equation model (also called the causal model), pathway analysis is a statistical method for representing causal relationships among the variables in the model \[[@b30-medscimonit-20-1155],[@b31-medscimonit-20-1155]\]. We believe this is the first series revealing the clinical pathway in tumor characteristics. [Figure 1B](#f1-medscimonit-20-1155){ref-type="fig"} shows the final model in this study. In this model, LVI, tumor size, and histology grade are important predictors of ALNM, which is compatible with findings reported in previous publications \[[@b15-medscimonit-20-1155]--[@b28-medscimonit-20-1155]\]. Presence of an HER2-positive tumor was identified as a predictor in the base of the model. HER2 status might influence ALNM through histology grade (β=0.18), and then tumor size (β=0.16). Tumor size was highly relevant to lymphovascular invasion and influenced ALNM through LVI (β=0.26). To apply this model in clinical practice, we suggest that LVI, tumor size, histology grade, and HER2 status are important predictors in assessment of axillary nodal status. If a patient is at high risk of ALNM in pre-operative cancer counseling, other advanced examinations (e.g., breast MR) and the possible need for a second axillary operation should be considered pre-operatively.

Recent data from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial suggest that ALND may be omitted in selected patients with less than 2 positive SLNs \[[@b32-medscimonit-20-1155]\]. In this study, 856 patients were enrolled and divided into 2 groups: ALND and SLND alone. Patient characteristics, including tumor size, ER, PR status, LVI, histology grade, tumor type, and lymph nodes metastases, were similar between the 2 groups. ALND may no longer be required in patients with the following characteristics: tumors smaller than 5 cm; fewer than 2 positive SLNs; without extracapsular extension; good patient acceptance; completion of whole breast radiation; and completion of adjuvant therapy, including hormonal, cytotoxic, or both. In this study, as in the ACOSOG study, tumor size was related with LVI, and LVI is the strongest predictor of ALNM. However, the aim of this study is different to that of the ACOSOG study. If a patient fulfills the ACOSOG study criteria, but with a larger tumor (T2) and LVI, according to our results the risk of ALNM is relatively higher. This study might suggest another option in surgical procedures (ALND or SLND) and post-operative treatment (e.g., chemotherapy and hormonal therapy).

Conclusions
===========

Four independent predictors of ALNM were identified. The strongest predictor of ALNM was LVI, followed by histology grade, tumor size, and HER2 status. Our structure equation model presented the relation of these important predictors. This model might help physicians to assess axillary nodal condition and determine appropriate surgical procedures.
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###### 

Patients' characteristics and tumor features.

  Variables                    Axillary lymph node metastases                                                                                  
  ---------------------------- -------------------------------- --------------- -------------------------------------------------------------- ---------------
  Age (mean ±SD)               51.12 (11.06)                    51.43 (11.38)   0.6154                                                         51.25 (11.20)
  **Clinical factors**                                                                                                                         
  Tumor size, mm (mean ± SD)   20.8 (1.164)                     29.1 (1.659)    \<0.0001[\*](#tfn1-medscimonit-20-1155){ref-type="table-fn"}   24.44 (1.461)
  Tumor size (mean ± SD)                                                                                                                       
   \<20 mm                     458 (61.73)                      211 (36.19)                                                                    669 (50.49)
   20--40 mm                   246 (33.15)                      286 (49.06)                                                                    532 (40.15)
   \>40 mm                     38 (5.12)                        86 (14.75)      \<0.0001[\*](#tfn1-medscimonit-20-1155){ref-type="table-fn"}   124 (9.36)
  Grade                                                                                                                                        
   I                           143 (19.27)                      72 (12.35)                                                                     215 (16.23)
   II                          415 (55.93)                      320 (54.89)                                                                    735 (55.47)
   III                         184 (24.80)                      191 (32.76)     0.0002[\*](#tfn1-medscimonit-20-1155){ref-type="table-fn"}     375 (28.30)
  **Pathological factors**                                                                                                                     
  Estrogen receptor                                                                                                                            
   Negative                    256 (34.50)                      177 (30.36)                                                                    433 (32.68)
   Positive                    486 (65.50)                      406 (69.64)     0.1106                                                         892 (67.32)
  Progesterone receptor                                                                                                                        
   Negative                    291 (39.22)                      183 (31.39)                                                                    474 (35.77)
   Positive                    451 (60.78)                      400 (68.61)     0.0032[\*](#tfn1-medscimonit-20-1155){ref-type="table-fn"}     851 (64.23)
  HER2                                                                                                                                         
   Negative                    616 (83.02)                      444 (76.16)                                                                    1060 (80.00)
   Positive                    126 (16.98)                      139 (23.84)     0.0019[\*](#tfn1-medscimonit-20-1155){ref-type="table-fn"}     265 (20.00)
  Lymphovascular invasion                                                                                                                      
   No                          585 (78.84)                      167 (28.64)                                                                    752 (56.75)
   Yes                         157 (21.16)                      416 (71.36)     \<0.0001[\*](#tfn1-medscimonit-20-1155){ref-type="table-fn"}   573 (43.25)

*p*\<0.01.

###### 

Logistic regression analysis of clinical and pathologic factors with axillary lymph node metastases.

  Variables                  Axillary lymph node metastases                                                                                          
  -------------------------- -------------------------------- -------------------------------------------------------------- ----------------------- --------------------------------------------------------------
  **Clinical factors**                                                                                                                               
  Tumor size, mm             1.559 (1.423--1.708)             \<0.0001[\*](#tfn2-medscimonit-20-1155){ref-type="table-fn"}   1.356 (1.228--1.498)    \<0.0001[\*](#tfn2-medscimonit-20-1155){ref-type="table-fn"}
  **Pathologic factors**                                                                                                                             
  Estrogen receptor                                                                                                                                  
   Positive *vs.* negative   1.208 (0.958--1.525)             0.1108                                                                                 
  Progesterone receptor                                                                                                                              
   Positive *vs.* negative   1.410 (1.122--1.773)             0.0032[\*](#tfn2-medscimonit-20-1155){ref-type="table-fn"}     1.329 (0.898--1.969)    0.156
  HER2                                                                                                                                               
   Positive *vs.* negative   1.531 (1.168--2.005)             0.0020[\*](#tfn2-medscimonit-20-1155){ref-type="table-fn"}     0.977 (0.531--1.799)    0.942
  Lymphovascular invasion                                                                                                                            
   Positive *vs.* negative   9.282 (7.218--11.936)            \<0.0001[\*](#tfn2-medscimonit-20-1155){ref-type="table-fn"}   8.219 (6.323--10.684)   \<0.0001[\*](#tfn2-medscimonit-20-1155){ref-type="table-fn"}
  Grade                                                                                                                                              
   II, III *vs.* I           1.694 (1.247--2.303)             0.0008[\*](#tfn2-medscimonit-20-1155){ref-type="table-fn"}     1.492 (1.034--2.152)    0.032[\*\*](#tfn3-medscimonit-20-1155){ref-type="table-fn"}

*p*\<0.01;

*p*\<0.05;

CI -- confidence interval.

###### 

Correlation coefficients among clinical and pathologic factors with axillary lymph node metastases.

                          Correlations                                                                                                                                                                                                                                     
  ----------------------- ----------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------- -------------------------------------------------------------
  Tumor size              0.281[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   1                                                                                                                                                                                    
  Progesterone receptor   0.081[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   −0.017                                                      1                                                                                                                        
  HER2                    0.085[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   0.102[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   −0.080[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   1                                                           
  LVI                     0.503[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   0.262[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   0.003                                                        0.036                                                       1
  Grade                   0.113[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   0.168[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   −0.148[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   0.178[\*](#tfn6-medscimonit-20-1155){ref-type="table-fn"}   0.069[\*\*](#tfn7-medscimonit-20-1155){ref-type="table-fn"}

Data were analyzed with Pearson correlation analysis.

Correlation is significant at the 0.01 level (two-tailed);

Correlation is significant at the 0.05 level (two-tailed).
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